Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01906632|
Recruitment Status : Recruiting
First Posted : July 24, 2013
Last Update Posted : July 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|Malignant Tumor||Biological: DC-CIK Immunotherapy||Not Applicable|
- The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) .
- Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing.
- The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。
- Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy.
- Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||May 2013|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 2020|
|gene expression profile||
Biological: DC-CIK Immunotherapy
- T-Cell Receptor/B-Cell Receptor gene expression [ Time Frame: 3 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01906632
|Contact: Jun Ren, MD, PhDemail@example.com|
|Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital||Recruiting|
|Beijing, China, 100038|
|Contact: Jun Ren, MD, PhD 86-10-63926317 firstname.lastname@example.org|